Q1 Earnings Estimate for ALNY Issued By HC Wainwright

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Alnylam Pharmaceuticals in a report released on Monday, February 24th. HC Wainwright analyst P. Trucchio anticipates that the biopharmaceutical company will post earnings of ($1.00) per share for the quarter. HC Wainwright has a “Buy” rating and a $500.00 price objective on the stock. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Alnylam Pharmaceuticals’ Q2 2025 earnings at ($1.02) EPS, Q3 2025 earnings at ($0.39) EPS, Q4 2025 earnings at $1.35 EPS, FY2025 earnings at ($1.05) EPS, FY2026 earnings at $11.93 EPS and FY2027 earnings at $26.01 EPS.

Several other analysts also recently weighed in on the company. Sanford C. Bernstein reduced their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. Chardan Capital reissued a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. Needham & Company LLC reissued a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 9th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $310.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $304.26.

Alnylam Pharmaceuticals Trading Down 0.5 %

NASDAQ:ALNY opened at $243.86 on Thursday. The stock has a 50-day simple moving average of $254.33 and a 200-day simple moving average of $262.59. The stock has a market cap of $31.57 billion, a P/E ratio of -112.38 and a beta of 0.35. Alnylam Pharmaceuticals has a 1 year low of $141.98 and a 1 year high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03).

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Allspring Global Investments Holdings LLC grew its holdings in Alnylam Pharmaceuticals by 62.2% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 161 shares during the last quarter. Wealth Enhancement Advisory Services LLC grew its holdings in Alnylam Pharmaceuticals by 56.2% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,454 shares of the biopharmaceutical company’s stock valued at $1,775,000 after buying an additional 2,323 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 41.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 11,528 shares of the biopharmaceutical company’s stock valued at $3,171,000 after buying an additional 3,373 shares during the last quarter. Pallas Capital Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 61.8% during the 3rd quarter. Pallas Capital Advisors LLC now owns 3,321 shares of the biopharmaceutical company’s stock valued at $975,000 after buying an additional 1,269 shares during the last quarter. Finally, New York State Teachers Retirement System acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at $1,453,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,986 shares of company stock worth $20,397,849. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.